Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Syndax Pharmaceuticals Inc SNDX

Healthcare Biotechnology
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing pipeline of cancer therapies. Its product candidates include revumenib, and axatilimab. It is developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:SNDX)

Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation

PR Newswire 6 days ago

Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib

PR Newswire 9 days ago

Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update

PR Newswire November 5, 2024

Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024

PR Newswire November 5, 2024

Syndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo(TM) (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting

PR Newswire November 5, 2024

Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting

PR Newswire November 5, 2024

Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo(TM)

PR Newswire November 4, 2024

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire November 1, 2024

Syndax Announces Participation in November Investor Conferences

PR Newswire November 1, 2024
View More News ››

Opinion & Analysis (NDAQ:SNDX)

Syndax Pharma Shares Rise on $35M Capital Raise, Credit Line and Positive Phase 1/2 Leukemia ...

Streetwise Reports February 3, 2020

2018 Biotech Watchlist: 'no one space is going to dominate'

Streetwise Reports January 11, 2018

2017 Small-Cap Biotech Watchlist update: up 21% at the end of Q2/17

The Life Sciences Report July 14, 2017

2017 Small-Cap biotech watchlist update: holding steady in a volatile market

The Life Sciences Report April 21, 2017

2017 Small-Cap Biotech Watchlist: takeaways for investors

The Life Sciences Report January 19, 2017

19 companies selected for the 2017 Small-Cap Biotech Watchlist

The Life Sciences Report January 5, 2017
View More Opinion ››

Bullboard Posts (NDAQ:SNDX)

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX): Poised for Trans

http://beyondspx.com/2024/08/01/syndax-pharmaceuticals-inc-nasdaqsndx-poised-for-transformative-growth-with-promising-pipeline-and...
MikeTester - August 1, 2024

4 BIOTECH STOCKS THAT WARRANT YOUR ATTENTION!

$SNDX $MTEM $STRO $KRYS Clinical-Stage companies offer an exciting investment opportunity with massive upside potential...
AviseAnalytics - October 5, 2021
View more Bullboard ››

LNG Energy Group Corp.

LNG Energy Group Corp.

LNG Energy Group Corp is a Canada-based company, which is focused on the acquisition and development of natural gas ...
View More »